Hennion & Walsh Asset Management, Inc. Amylyx Pharmaceuticals, Inc. Transaction History
Hennion & Walsh Asset Management, Inc.
- $2.1 Billion
- Q4 2024
A detailed history of Hennion & Walsh Asset Management, Inc. transactions in Amylyx Pharmaceuticals, Inc. stock. As of the latest transaction made, Hennion & Walsh Asset Management, Inc. holds 90,619 shares of AMLX stock, worth $312,635. This represents 0.02% of its overall portfolio holdings.
Number of Shares
90,619
Previous 114,534
20.88%
Holding current value
$312,635
Previous $371,000
8.09%
% of portfolio
0.02%
Previous 0.02%
Shares
9 transactions
Others Institutions Holding AMLX
# of Institutions
126Shares Held
44.3MCall Options Held
235KPut Options Held
530K-
Tcg Crossover Management, LLC Palo Alto, CA4.64MShares$16 Million1.95% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.09MShares$10.7 Million0.0% of portfolio
-
Black Rock Inc. New York, NY2.67MShares$9.21 Million0.0% of portfolio
-
Perceptive Advisors LLC New York, NY2.13MShares$7.33 Million0.18% of portfolio
-
Alyeska Investment Group, L.P. Chicago, IL2.02MShares$6.98 Million0.04% of portfolio
About Amylyx Pharmaceuticals, Inc.
- Ticker AMLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,533,200
- Market Cap $202M
- Description
- Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...